SNCA and Parkinson disease: Usage of both non-motor clinical and biomarker variables may lend clinical variables (notably hyposmia and RBDQ) enhanced PD-specific responsiveness, a heightened PD-specific responsiveness derived from biomarker (possibly alpha synuclein) putative PD-specific sensitivity (43).